185 related articles for article (PubMed ID: 35183560)
1. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.
Zephyr J; Nageswara Rao D; Vo SV; Henes M; Kosovrasti K; Matthew AN; Hedger AK; Timm J; Chan ET; Ali A; Kurt Yilmaz N; Schiffer CA
J Mol Biol; 2022 May; 434(9):167503. PubMed ID: 35183560
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
Timm J; Kosovrasti K; Henes M; Leidner F; Hou S; Ali A; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2020 Feb; 15(2):342-352. PubMed ID: 31868341
[TBL] [Abstract][Full Text] [Related]
3.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
4. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
6. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.
Nageswara Rao D; Zephyr J; Henes M; Chan ET; Matthew AN; Hedger AK; Conway HL; Saeed M; Newton A; Petropoulos CJ; Huang W; Kurt Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2021 Aug; 64(16):11972-11989. PubMed ID: 34405680
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
[TBL] [Abstract][Full Text] [Related]
9. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
[TBL] [Abstract][Full Text] [Related]
10. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Cotter TG; Jensen DM
Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
[TBL] [Abstract][Full Text] [Related]
11. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
Miao M; Jing X; De Clercq E; Li G
Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
[TBL] [Abstract][Full Text] [Related]
12. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
Bu G; Danelius E; Wieske LHE; Gonen T
Adv Biol (Weinh); 2024 May; 8(5):e2300570. PubMed ID: 38381052
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir/Pibrentasvir: First Global Approval.
Lamb YN
Drugs; 2017 Oct; 77(16):1797-1804. PubMed ID: 28929412
[TBL] [Abstract][Full Text] [Related]
17. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
18.
Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
Matthew AN; Leidner F; Newton A; Petropoulos CJ; Huang W; Ali A; KurtYilmaz N; Schiffer CA
Structure; 2018 Oct; 26(10):1360-1372.e5. PubMed ID: 30146168
[TBL] [Abstract][Full Text] [Related]
20. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
